Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Free Cash Flow (2016 - 2025)

KalVista Pharmaceuticals' Free Cash Flow history spans 10 years, with the latest figure at -$40.7 million for Q2 2025.

  • For Q2 2025, Free Cash Flow fell 162.98% year-over-year to -$40.7 million; the TTM value through Apr 2025 reached -$120.7 million, down 34.66%, while the annual FY2025 figure was -$153.4 million, 71.15% down from the prior year.
  • Free Cash Flow for Q2 2025 was -$40.7 million at KalVista Pharmaceuticals, down from -$39.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$15.5 million in Q2 2024 and bottomed at -$40.7 million in Q2 2025.
  • The 3-year median for Free Cash Flow is -$27.6 million (2024), against an average of -$30.0 million.
  • The largest annual shift saw Free Cash Flow crashed 50.51% in 2024 before it plummeted 162.98% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$19.8 million in 2023, then crashed by 100.48% to -$39.8 million in 2024, then dropped by 2.41% to -$40.7 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Free Cash Flow are -$40.7 million (Q2 2025), -$39.8 million (Q4 2024), and -$40.2 million (Q3 2024).